Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn’s disease, the company announced. Still recruiting ... Read more
Inhibiting the inflammatory molecule Fn14 with new compounds or antibodies may reduce inflammation and tissue scarring in people with Crohn’s disease, a study suggests. The study, “TWEAK/Fn14 Is Overexpressed ... Read more
A larger proportion of people treated with the highest dose of InDex Pharmaceuticals‘ investigational therapy cobitolimod achieved clinical remission compared with those treated with placebo, according to the results ... Read more
Despite the popular belief that smoking may provide a protective effect for patients with ulcerative colitis (UC), a recent large-scale study found no benefits from smoking in patients with ... Read more
Canada has become the first country to fully authorize a Phase 2b clinical trial that will explore Abivax‘s lead candidate ABX464 in patients with ulcerative colitis, the company announced. ... Read more
An international research team has sequenced and archived the world’s most comprehensive collection of human gut bacteria, identifying a total of 105 new species of bacteria that naturally populate ... Read more
The European commission (EC) has granted marketing authorization to Mylan and Fujifilm Kyowa Kirin Biologics for Hulio, a biosimilar to AbbVie’s Humira (adalimumab). The marketing authorization covers all indications for ... Read more